| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2017: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2016: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
Interferon-β(IFNβ) is a cytokine with pleiotropic and potent bioactivity. In this study, effective IFNβ gene therapy was developed. First, a plasmid vector named as pMX- IFNβ, which is driven by Mx promoter, was developed to achieve sustained IFNβ transgene expression. Sustained IFNβ expression from pMX- IFNβ was effective in treating cancer and multiple sclerosis (MS) in model mice. Moreover, by designing a fusion protein of galectin-9 (gal9) and IFNβ named as IFNβ-gal9, it was succeeded in improving therapeutic effect of IFNβ on MS and reducing adverse effect of IFNβ. In conclusion, IFN gene therapy with high therapeutic index was successfully developed.
|
